

Bacterial Infection

**A study to look at how safe different doses of a new medicine called “DSTA4637S” were for patients – and how this medicine was processed through the body**

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

**Trial Status**  
Completed

**Trial Runs In**  
3 Countries

**Trial Identifier**  
NCT03162250 2016-001880-35  
GV39131

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S when given in addition to anti-staphylococcal SOC antibiotics to participants with methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (MSSA) bacteremia requiring at least 4 weeks of anti-staphylococcal SOC antibiotics.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT03162250 2016-001880-35 GV39131**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 80 Years

**Healthy Volunteers**  
No

---

This clinical trial was done to study a new medicine called, “DSTA4637S”, for the treatment of patients with infections caused by bacteria named Staphylococcus aureus. This study investigated the side effects caused by this medicine. Researchers were also interested to find out what happens to the medicine inside the body of patients.

# ForPatients

*by Roche*

Twenty-five patients with *S. aureus* infection took part in the study at 17 study centers in 3 countries.